H R Hygiene Products IPO

Does stock fall in these catagories?: Brand Creation Strategy: The company is actively building its own consumer brands Femis, Womanika, Elderfit, Bloom Baby and establishing a retail presence, showing an intent to move beyond just being a contract manufacturer. Valuation Metrics At Face Value: Based on the reported ₹11 crore profit, the P/E ratio is around 18-19x, and the Price-to-Book P/B ratio is approximately 2.5x, which appears superficially attractive for the sector. Key Risks Discussed: 1. Questionable Financials & Inflation: There is a significant mismatch between revenue growth and actual cash flow. The transcript suggests "artificial growth" created by inflating trade receivables and inventory to make the company look more valuable for the IPO. 2. Concentration Risk: Roughly 50% of revenue comes from a single customer a third-party contractor for government orders, and other key customers have reduced their order volumes. 3. Governance & Management Integrity: Promoters are taking money out of the company via the IPO OFS while the company itself is struggling with working capital, indicating management may be prioritizing personal gain over business health. 4. Operational Discrepancies: Despite high capacity utilization, the cost of materials consumed has spiked without a logical explanation, and the company relies heavily on trading rather than manufacturing. 5. Stuck Receivables: A substantial amount approx. ₹25 crore is stuck as trade receivables, with significant portions aged 1–2 years, yet categorized as "good" by the company. 6. Poor IPO Track Record: The intermediaries brokers associated with this IPO have a history of bringing companies to market that list poorly or show negative performance post-listing.